Praxis Precision Medicines Advances Precision Therapies for CNS Disorders, Anticipates Key Milestones in Seizure and Pediatric Epilepsy Treatment
Praxis Precision Medicines Advances Precision Therapies for CNS Disorders, Anticipates Key Milestones in Seizure and Pediatric Epilepsy Treatment
Praxis Precision Medicines推進中樞神經系統疾病的精準療法，預測癲癇發作和小兒癲癇治療的關鍵里程碑
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2024.
Praxis Precision Medicines, Inc.（納斯達克股票代碼：PRAX）是一家臨床階段的生物製藥公司，將遺傳見解轉化爲以神經元興奮抑制失衡爲特徵的中樞神經系統（CNS）疾病療法的開發，今天提供了公司最新情況並公佈了2024年第一季度的財務業績。
"In the first quarter we made significant progress on all fronts. We strengthened our financial resources and reported positive photo paroxysmal response (PPR) results in PRAX-628, which we believe further de-risks our clinical development program and positions PRAX-628 as the first precision sodium channel modulator for focal onset seizures. The strength and consistency observed across...
“在第一季度，我們在各個方面都取得了重大進展。我們加強了財政資源，並報告了 PRAX-628 的陽性照片陣發性反...
登入免費觀看全文
登入/註冊